Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

Summary

The most notable tolerability finding from these multiple dosing studies has been the occurrence of mild to moderate rash at doses of 450 mg BID and 600 mg BID. Based upon this finding, the current four week study is designed to examine whether a slow titration regimen up to a lower maintenance dose of 450 mg BID is able to reduce the incidence of rash.

Timeline

Start

2013-01

Primary completion

2013-04

Completion

2013-04

Drugs

Indications

No indication recorded.